-
公开(公告)号：US20250066492A1
公开(公告)日：2025-02-27
申请号：US18886853
申请日：2024-09-16
Applicant: BIOINVENT INTERNATIONAL AB
Inventor： Björn FRENDÉUS , Ingrid TEIGE , Linda MÅRTENSSON , Petra HOLMKVIST , Monika SEMMRICH
IPC: C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61P35/00
Abstract: Described are novel antibody molecules that specifically bind to TNFR2 on a target cell and thereby agonize TNFR2, but that do not block the ligand TNF-α from binding to the TNFR2. Also described is the use of such antibody molecules in medicine, i.a. in treatment of cancer or chronic inflammatory diseases.
-
2.发明申请公开(公告)号：US20200207855A1
公开(公告)日：2020-07-02
申请号：US16633740
申请日：2018-07-26
Inventor： Björn FRENDÉUS , Linda MÅRTENSSON , Monika SEMMRICH , Ingrid TEIGE , Stephen BEERS , Aymen AL-SHAMKHANI , Juliet GRAY , Martin GLENNIE
IPC: C07K16/28
Abstract: Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
-
公开(公告)号：US20220073634A1
公开(公告)日：2022-03-10
申请号：US17290352
申请日：2019-11-01
Applicant: BIOINVENT INTERNATIONAL AB
Inventor： Björn FRENDÉUS , Ingrid TEIGE , Linda MÅRTENSSON , Petra HOLMKVIST , Monika SEMMRICH
Abstract: Described are novel antagonistic antibody molecules that specifically bind to TNFR2 on a target cell and thereby block TNF-α binding to TNFR2 and block TNFR2 signaling, wherein the antibody molecules also bind to Fc receptors via the Fc region. Also described is the use of such antibody molecules in treatment of cancer or infections caused by intracellular pathogens.
-
公开(公告)号：US20240301070A1
公开(公告)日：2024-09-12
申请号：US18008141
申请日：2021-06-04
Applicant: BIOINVENT INTERNATIONAL AB
Inventor： Björn FRENDÉUS , Linda MÅRTENSSON , Ingrid TEIGE , Ingrid KARLSSON
CPC classification number: C07K16/283 , A61K9/0019 , A61P35/00 , A61K2039/505 , A61K2039/545
Abstract: The present invention generally relates to combinations for use in therapeutic systems and antibody dosage regimens, and uses thereof. Also described herein is a model for predicting if a therapeutic antibody binding to a human target will be associated with a tolerability issue in connection with intravenous administration and/or for predicting if pre-treatment, altered administration route or modification of the antibody can prevent a tolerability issue associated with intravenous administration to a human of the therapeutic antibody. The model comprises administering the antibody intravenously or intraperitoneally to mice and observing the mice immediately after the administration for any transient display of the macroscopic symptoms isolation and decreased activity. The model may also comprise administration of a pre-treatment in combination with administration of the antibody, administration of the therapeutic antibody by a route of administration other than intravenous or intraperitoneal administration or administration of a modified format of the antibody to mice and observing the mice immediately after such administration for any transient display of the macroscopic symptoms isolation and decreased activity and comparing this with the transient display of the macroscopic symptoms isolation and decreased activity after the intravenous or intraperitoneal administration of the unmodified antibody without pre-treatment.
-
Patent Agency Ranking
公开(公告)号：US20240092912A1
公开(公告)日：2024-03-21
申请号：US18281530
申请日：2022-03-09
Applicant: BIOINVENT INTERNATIONAL AB , UNIVERSITY OF SOUTHAMPTON
Inventor： Björn FRENDÉUS , Linda MÅRTENSSON , Ingrid TEIGE , Mark CRAGG , Robert OLDHAM , Stephen BEERS , Ali ROGHANIAN
CPC classification number: C07K16/283 , A61P35/00 , C07K16/2818 , C07K16/2827 , A61K2039/507
Abstract: The present invention generally relates to antibody combinations and uses thereof.
-
6.发明公开公开(公告)号：US20230322933A1
公开(公告)日：2023-10-12
申请号：US18008134
申请日：2021-06-04
Applicant: BIOINVENT INTERNATIONAL AB
Inventor： Björn FRENDÉUS , Linda MARTENSSON , Ingrid TEIGE , Ingrid KARLSSON
IPC: C07K16/28 , A61K49/00 , A61K31/573 , A61K31/341 , A61K9/00 , A61K39/395
CPC classification number: C07K16/283 , A61K49/0008 , A61K31/573 , A61K31/341 , A61K9/0019 , A61K39/3955 , A61K2039/54
Abstract: The present invention generally relates to combinations for use in therapeutic systems and antibody dosage regimens, and uses thereof. Also described herein is a model for predicting if a therapeutic antibody binding to a human target will be associated with a tolerability issue in connection with intravenous administration and/or for predicting if pre-treatment, altered administration route or modification of the antibody can prevent a tolerability issue associated with intravenous administration to a human of the therapeutic antibody. The model comprises administering the antibody intravenously or intraperitoneally to mice and observing the mice immediately after the administration for any transient display of the macroscopic symptoms isolation and decreased activity. The model may also comprise administration of a pre-treatment in combination with administration of the antibody, administration of the therapeutic antibody by a route of administration other than intravenous or intraperitoneal administration or administration of a modified format of the antibody to mice and observing the mice immediately after such administration for any transient display of the macroscopic symptoms isolation and decreased activity and comparing this with the transient display of the macroscopic symptoms isolation and decreased activity after the intravenous or intraperitoneal administration of the unmodified antibody without pre-treatment.
-
7.发明申请公开(公告)号：US20230058227A1
公开(公告)日：2023-02-23
申请号：US17819234
申请日：2022-08-11
Inventor： Björn FRENDÉUS , Linda MÅRTENSSON , Monika SEMMRICH , Ingrid TEIGE , Stephen BEERS , Aymen AL-SHAMKHANI , Juliet GRAY , Martin GLENNIE
IPC: C07K16/28
Abstract: Described is the sequential administration of first a Treg depleting antibody mole-cute selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. De-scribed are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
-
公开(公告)号：US20220259309A1
公开(公告)日：2022-08-18
申请号：US17627385
申请日：2020-07-17
Applicant: BIOINVENT INTERNATIONAL AB , UNIVERSITY OF SOUTHAMPTON
Inventor： Björn FRENDÉUS , Ingrid TEIGE , Linda MÅRTENSSON , Ingrid KARLSSON , Mark CRAGG , Stephen BEERS , Robert OLDHAM
Abstract: Described is the combined use of a first antibody molecule that specifically binds FcyRIIb via its Fab region and that binds an Fey receptor via its Fc region, and a second antibody molecule that specifically binds PD-1 and that binds at least one Fey receptor via its Fc region, in the treatment of cancer in a patient having tumor infiltrating T lymphocytes with a medium or high PD-1 expression, as well as pharmaceutical compositions and kits comprising these two antibody molecules, and methods of treating cancer using these two antibodies. Described is also a diagnostic test for identification of patients benefitting from the treatment described herein.
-
公开(公告)号：US20220002426A1
公开(公告)日：2022-01-06
申请号：US17290340
申请日：2019-11-01
Applicant: BIOINVENT INTERNATIONAL AB
Inventor： Björn FRENDÉUS , Ingrid TEIGE , Linda MÅRTENSSON , Petra HOLMKVIST , Monika SEMMRICH
IPC: C07K16/28 , A61K45/06 , A61K39/395 , A61P35/00
Abstract: Described are novel antibody molecules that specifically bind to TNFR2 on a target cell and thereby agonize TNFR2, but that do not block the ligand TNF-α from binding to the TNFR2. Also described is the use of such antibody molecules in medicine, i.a, in treatment of cancer or chronic inflammatory diseases.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.016 seconds)
